Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
Eli Lilly logo
Eli LillyLLY
$7.4B+168%
Pfizer logo
PfizerPFE
$2.7B-9.3%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$453.82M-113%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$45.51M-14.1%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s net income?
Erasca, Inc. (ERAS) reported net income of -$183.44M in Q1 2026.
How has Erasca, Inc.'s net income changed year-over-year?
Erasca, Inc.'s net income decreased by 492.4% year-over-year, from -$30.97M to -$183.44M.
What is the long-term trend for Erasca, Inc.'s net income?
Over 4 years (2021 to 2025), Erasca, Inc.'s net income has grown at a 0.4% compound annual growth rate (CAGR), from -$122.76M to -$124.55M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.